<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01432483</url>
  </required_header>
  <id_info>
    <org_study_id>E7272-A001-401</org_study_id>
    <nct_id>NCT01432483</nct_id>
  </id_info>
  <brief_title>Access Program With Denileukin Diftitox for the Treatment of Patients Currently Receiving Treatment With Commercially Available (Ontak)</brief_title>
  <official_title>Access Program With Denileukin Diftitox for the Treatment of Patients Currently Receiving Treatment With Commercially Available (Ontak)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to provide continued therapy with Denileukin diftitox (ONTAK) to
      patients who are currently on therapy and who have no other suitable treatment options, where
      therapy is requested by their physician.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Access Program will be provided as long as appropriate according to the judgment of the
      provider. If Denileukin diftitox (ONTAK) becomes commercially available without restriction,
      then the access program will be discontinued.
    </textblock>
  </detailed_description>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <condition>Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Denileukin diftitox (ONTAK)</intervention_name>
    <description>Given at a dose of 9 or 18mcg/kg/day by intravenous infusion over 30 to 60 minutes for 5 consecutive days every 21 days for 8 cycles.</description>
    <other_name>ONTAK</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        To receive denileukin diftitox (ONTAK) under this protocol, the patient's physician must
        request this therapy for the specific patient. Patients may continue treatment with
        denileukin diftitox if they:

          -  Are currently on therapy with denileukin diftitox and require ongoing therapy to
             maintain control of their disease.

          -  Are willing and able to comply with all aspects of the Access Protocol

          -  Provide written informed consent to participate

        Exclusion Criteria:

        Patients are not eligible for the Access Program with denileukin diftitox if they:

        â€¢ Are not currently on denileukin diftitox therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Gary Palmer, MD</last_name>
    <role>Study Director</role>
    <affiliation>Eisai Inc.</affiliation>
  </overall_official>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2011</study_first_submitted>
  <study_first_submitted_qc>September 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2011</study_first_posted>
  <last_update_submitted>January 22, 2015</last_update_submitted>
  <last_update_submitted_qc>January 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>ONTAK</keyword>
  <keyword>Denileukin diftitox</keyword>
  <keyword>persistent or recurrent disease</keyword>
  <keyword>requiring continued delivery of essential cancer therapy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denileukin diftitox</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

